Update on treatment of polymyalgia rheumatica.
Reumatismo
; 70(1): 59-66, 2018 Mar 27.
Article
em En
| MEDLINE
| ID: mdl-29589404
ABSTRACT
Polymyalgia rheumatica (PMR) is the second most common inflammatory rheumatic disease in the elderly after rheumatoid arthritis. It is clinically characterised by pain and stiffness in the neck, proximal shoulder and hip girdle. Glucocorticoids (GCs) are the cornerstone of PMR treatment, but they are associated with potentially severe side effects. Among GC-sparing agents, methotrexate revealed a modest benefit in clinical trials, and recently, there have been promising reports from tocilizumab. In this review, we summarize the available evidence on the treatment of PMR and the possible role in the future of other agents under investigation.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Polimialgia Reumática
/
Metotrexato
/
Antirreumáticos
/
Anticorpos Monoclonais Humanizados
/
Glucocorticoides
Limite:
Aged
/
Humans
Idioma:
En
Revista:
Reumatismo
Ano de publicação:
2018
Tipo de documento:
Article